Remidio receives CDSCO approval for AI Tools to Detect Glaucoma and AMD
State FDA, Karnataka, clears Medios HI Glaucoma AI and Medios HI AMD AI for nationwide use, expanding access to early detection tools in ophthalmology
Remidio Innovative Solutions has received regulatory approval from the State FDA, Karnataka (CDSCO) for its AI-based tools Medios HI Glaucoma AI and Medios HI AMD AI for use across India. The CDSCO is the designated authority overseeing medical device regulation in the country. The company stated that this development marks an expansion in the application of artificial intelligence for early detection of glaucoma and age-related macular degeneration (AMD) in various healthcare settings.
The approval follows the deployment of Medios DR HI, an AI solution for diabetic retinopathy, also cleared by CDSCO. According to the company, the diabetic retinopathy AI has screened nearly 2,50,000 patients in the past year. The glaucoma and AMD tools are designed to work offline, enabling use in areas with limited internet access.
